Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HDP-101 |
Synonyms | |
Therapy Description |
HDP-101 is an antibody-drug conjugate (ADC) comprising an antibody targeting the anti-B cell maturation antigen (BCMA) linked to a derivative of amanitin, which binds to BCMA-positive tumor cells, potentially leading to induction of apoptosis, tumor cell killing, and inhibition of tumor growth (PMID: 33298585). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HDP-101 | HDP101 | TNFRSF17 Antibody 20 | HDP-101 is an antibody-drug conjugate (ADC) comprising an antibody targeting the anti-B cell maturation antigen (BCMA) linked to a derivative of amanitin, which binds to BCMA-positive tumor cells, potentially leading to induction of apoptosis, tumor cell killing, and inhibition of tumor growth (PMID: 33298585). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04879043 | Phase Ib/II | HDP-101 | Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma | Recruiting | USA | POL | HUN | DEU | 0 |